Annual report pursuant to Section 13 and 15(d)

14. Related Party Transactions (Details Narrative)

v3.20.1
14. Related Party Transactions (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Research and development expense $ 4,889,340 $ 2,883,952
Advanced payment 722,079 $ 555,856
Pharmsynthez [Member] | Sponsored Research Agreement [Member]    
Research and development expense 155,000  
Payment for research agreement 350,000  
Advanced payment 195,000  
Pharmsynthez [Member] | Co-Development Agreement [Member]    
Payment for note receivable $ 500,000  
Note receivable interest rate 10.00%  
Interest income $ 9,000  
Hesperix [Member]    
Loan payable $ 225,000